Source · Select Committees · Health and Social Care Committee

Tenth Report - Prevention in health and social care: vaccination

Health and Social Care Committee HC 1764 Published 27 July 2023
Report Status
Government responded
Conclusions & Recommendations
10 items (6 recs)
Government Response
AI assessment · 10 of 10 classified
Accepted 6
Accepted in Part 2
Deferred 2
Filter by: Clear

Recommendations

3 results
6 Accepted

Provide Government commitment and support to NHS England's vaccination and immunisation strategy.

Recommendation
We welcome NHS England’s intention to set out an integrated vaccination and immunisation strategy. This strategy will be vital if England is to meet the 95% target for all childhood vaccinations and to address the variations in uptake across routine … Read more
Government Response Summary
The government confirms that NHS England, in collaboration with partners, is developing an integrated vaccination and immunisation delivery strategy to improve uptake and coverage, which will be published later in 2023.
Department of Health and Social Care
View Details →
7 Accepted
Para 28

Require NHS England's strategy to address access, professional roles, local empowerment, and communication.

Recommendation
The NHS England integrated vaccination and immunisation strategy must: a) have a strong focus on the action that is needed to tackle the practical challenges that limit access to vaccination; b) set out how to make best use of the … Read more
Government Response Summary
The government states NHS England is developing an integrated vaccination and immunisation delivery strategy, due for publication later in 2023, which will address the committee's points by focusing on local empowerment, diverse healthcare professionals, and targeted outreach.
Department of Health and Social Care
View Details →
9 Accepted
Para 34

Swiftly implement O’Shaughnessy review recommendations for clinical trials and patient engagement.

Recommendation
We welcome Lord O’Shaughnessy’s review of commercial clinical trials, which chimed with a lot of the evidence that we heard in this part of our inquiry. The Government’s positive response to the recommendations is encouraging. We especially endorse the following … Read more
Government Response Summary
The government accepts the recommendations in principle, noting it has made five headline commitments backed by £121 million to improve commercial clinical trials and will provide an implementation update in the autumn outlining progress and responding in full to the remaining review recommendations.
Department of Health and Social Care
View Details →

Conclusions (3)

Observations and findings
2 Conclusion Accepted
Para 17
Vaccination is the one of the greatest success stories when it comes to preventing infection. Its impact is transformative. This makes it all the more concerning that England did not reach the 95% target for any routine childhood immunisations in 2021/22. The Government and NHS England should constantly strive to …
Government Response Summary
NHS England, in collaboration with partners, is developing and will publish a vaccination and immunisation delivery strategy later in 2023, aimed at improving uptake and coverage, reducing inequalities, and delivering locally tailored services with targeted outreach.
View Details →
5 Conclusion Accepted
Para 26
We agree that there is a need for national oversight of vaccination programmes and the value of this was clear during the Covid-19 pandemic. However, with routine immunisation programmes, the role of the Government and, in particular, NHS England must be limited to the more strategic, national level. Local ICS …
Government Response Summary
The government described existing national oversight roles (DHSC, UKHSA, JCVI) and processes for new immunisation products. It stated it is working with JCVI and UKHSA to support resources for outbreak response and improvement of existing programmes, and mentioned funding for MHRA to bring innovative medicines to market.
View Details →
8 Conclusion Accepted
Para 33
We are deeply concerned to hear about the decline in clinical trial activity and the risk to the UK’s position as a global leader in this area. The challenges highlighted by witnesses, particularly around the administrative aspects of running a trial, are clearly fixable and it is vital that they …
Government Response Summary
The government notes the concerns about clinical trial decline but highlights an increase in participants since 2018 and the impact of the pandemic. It details existing efforts like the Research Reset programme and the 'Future of UK Clinical Research Delivery' strategy, reaffirming its commitment to regaining global leadership.
View Details →